The Centre for Medicines Discovery aims to catalyse the discovery and development of new medicines for patients.
Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection
22 October 2021
From the Sanyal & Kessler labs and collaborators, read about our research findings on the biology of cytokine storms triggered by SARS-CoV-2.
13 October 2021
The Behrens (ICR) and Kessler labs show that ubiquitin-specific protease 28 (USP28) is required for the survival of lung squamous cell carcinomas (LSCCs). Using genetic knockout models and a novel small molecule inhibitor of USP28, we demonstrate loss or inhibition of USP28 impairs the growth of LSCCs to a much greater degree than lung adenocarcinomas, associated with a greater degree of loss of c-MYC, c-JUN, and DP63. This work will be of interest to researchers seeking to better understand and treat LSCCs.
23 July 2021
Professor Frank von Delft is co-founder of the Moonshot project, which is a collaboration of expertise from all over the world. Thanks to the light beam work at Diamond, chemists now know the virus' weak spots and can work on developing a new anti-viral drug.
The Target Enabling Package on #TREM2 for #AlzheimersDisease includes investigations on binding modes & functional activity of scFv antibody fragments. In collaboration with @ARUK_ODDI @karolinskainst @thesgconline @KTHresearch @EisaiUS & VivaBiotech. https://doi.org/10.5281/zenodo.5256633
Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection.
Munnur D. et al, (2021), Nat Immunol
Turning high-throughput structural biology into predictive inhibitor design
Saar K. et al, (2021)
USP28 deletion and small molecule inhibition destabilises c-MYC and elicits regression of squamous cell lung carcinoma.
Ruiz EJ. et al, (2021), Elife, 10